Transcriptional regulation of DLGAP5 by AR suppresses p53 signaling and inhibits CD8T cell infiltration in triple-negative breast cancer.

Qing Pan, Dachang Ma, Yi Xiao, Kun Ji, Jun Wu
Author Information
  1. Qing Pan: Department of Galactophore, The First Hospital of Lanzhou University, Lanzhou 730000, PR China.
  2. Dachang Ma: Department of Galactophore, The First Hospital of Lanzhou University, Lanzhou 730000, PR China.
  3. Yi Xiao: Department of Galactophore, The First Hospital of Lanzhou University, Lanzhou 730000, PR China.
  4. Kun Ji: Department of Galactophore, The First Hospital of Lanzhou University, Lanzhou 730000, PR China.
  5. Jun Wu: Department of Galactophore, The First Hospital of Lanzhou University, Lanzhou 730000, PR China. Electronic address: ery_wujun@lzu.edu.cn.

Abstract

Triple-negative breast cancer (TNBC) is a challenging subtype with unclear biological mechanisms. Recently, the transcription factor androgen receptor (AR) and its regulation of the DLGAP5 gene have gained attention in TNBC pathogenesis. In this study, we found a positive correlation between high AR expression and TNBC cell proliferation and growth. Furthermore, we confirmed DLGAP5 as a critical downstream regulator of AR with high expression in TNBC tissues. Knockdown of DLGAP5 significantly inhibited TNBC cell proliferation, migration, and invasion. AR was observed to directly bind to the DLGAP5 promoter, enhancing its transcriptional activity and suppressing the activation of the p53 signaling pathway. In vivo experiments further validated that downregulation of AR or DLGAP5 inhibited tumor growth and enhanced CD8T cell infiltration. This study highlights the crucial roles of AR and DLGAP5 in TNBC growth and immune cell infiltration. Taken together, AR inhibits the p53 signaling pathway by promoting DLGAP5 expression, thereby impacting CD8T cell infiltration in TNBC.

Keywords

References

  1. BMC Genomics. 2022 Jan 5;23(1):5 [PMID: 34983375]
  2. Sci Rep. 2017 Feb 24;7:43180 [PMID: 28233861]
  3. Cell Death Dis. 2020 Jul 27;11(7):589 [PMID: 32719347]
  4. Tissue Eng Regen Med. 2021 Aug;18(4):641-650 [PMID: 34275104]
  5. Cancers (Basel). 2020 Apr 08;12(4): [PMID: 32276534]
  6. Nutrients. 2020 Feb 05;12(2): [PMID: 32033291]
  7. Nat Biotechnol. 2019 Jul;37(7):773-782 [PMID: 31061481]
  8. Breast Cancer Res Treat. 2015 Nov;154(2):225-37 [PMID: 26487496]
  9. BMC Womens Health. 2023 Apr 11;23(1):169 [PMID: 37041633]
  10. J Proteomics. 2022 Apr 30;258:104543 [PMID: 35231659]
  11. J Hematol Oncol. 2022 Aug 29;15(1):121 [PMID: 36038913]
  12. Pharmacol Ther. 2022 Sep;237:108253 [PMID: 35872332]
  13. Cancer Med. 2023 Aug;12(15):16295-16309 [PMID: 37329188]
  14. Nat Cancer. 2020 Mar;1(3):291-301 [PMID: 32566933]
  15. Cancer Res. 2012 May 1;72(9):2294-303 [PMID: 22396495]
  16. Cancer Cell. 2023 Mar 13;41(3):585-601.e8 [PMID: 36827978]
  17. Sci Rep. 2021 Oct 21;11(1):20799 [PMID: 34675265]
  18. Endocrinology. 2021 Aug 1;162(8): [PMID: 34038515]
  19. Cell Res. 2022 Jun;32(6):530-542 [PMID: 35165422]
  20. OMICS. 2012 May;16(5):284-7 [PMID: 22455463]
  21. Int J Mol Sci. 2022 Sep 29;23(19): [PMID: 36232774]
  22. J Cancer Res Clin Oncol. 2023 Jul;149(8):4639-4651 [PMID: 36175801]
  23. Biomedicines. 2021 Jul 23;9(8): [PMID: 34440080]
  24. Sci Rep. 2021 Feb 25;11(1):4691 [PMID: 33633150]
  25. Int J Mol Sci. 2023 Oct 31;24(21): [PMID: 37958803]
  26. Front Immunol. 2021 Jul 20;12:715234 [PMID: 34354714]
  27. Cell Metab. 2022 Apr 5;34(4):581-594.e8 [PMID: 35278352]
  28. Exp Ther Med. 2021 Nov;22(5):1245 [PMID: 34539841]
  29. Breast Cancer Res. 2023 Jul 17;25(1):85 [PMID: 37461019]
  30. Breast Cancer Res. 2020 Jun 9;22(1):61 [PMID: 32517735]
  31. Int J Biol Sci. 2021 May 11;17(8):2069-2079 [PMID: 34131406]
  32. Mol Biol Rep. 2022 Apr;49(4):3055-3064 [PMID: 35032258]
  33. J Cancer Res Clin Oncol. 2019 Mar;145(3):661-673 [PMID: 30643969]
  34. Nat Biotechnol. 2018 Jun;36(5):411-420 [PMID: 29608179]
  35. Cells. 2019 Aug 14;8(8): [PMID: 31416135]
  36. Oncol Lett. 2020 Jun;19(6):4053-4065 [PMID: 32391106]
  37. Cell Physiol Biochem. 2017;43(6):2212-2225 [PMID: 29069648]
  38. Mol Plant Pathol. 2022 Mar;23(3):417-430 [PMID: 34851539]
  39. Leukemia. 2022 Aug;36(8):2108-2120 [PMID: 35790816]
  40. JAMA. 2020 Feb 11;323(6):548-560 [PMID: 32044947]
  41. Front Immunol. 2020 Nov 10;11:565470 [PMID: 33244315]
  42. Matrix Biol. 2022 Feb;106:1-11 [PMID: 35045313]
  43. Cancer Cell Int. 2020 Aug 08;20:382 [PMID: 32782440]
  44. Cell Oncol (Dordr). 2020 Apr;43(2):321-333 [PMID: 31933152]
  45. Cancer Res. 2021 Feb 01;81(4 Suppl): [PMID: 34421401]
  46. J Cell Physiol. 2019 Sep;234(9):16540-16548 [PMID: 30805932]
  47. Hum Cell. 2023 May;36(3):1108-1119 [PMID: 36897549]
  48. J Oncol Pharm Pract. 2023 Sep;29(6):1467-1479 [PMID: 37559370]
  49. Cancer Treat Rev. 2017 Dec;61:15-22 [PMID: 29078133]
  50. Cell. 2022 Jul 21;185(15):2770-2788 [PMID: 35835100]
  51. Science. 2022 Feb 25;375(6583):877-884 [PMID: 35113651]
  52. Technol Cancer Res Treat. 2021 Jan-Dec;20:1533033820983298 [PMID: 33499770]
  53. Diagnostics (Basel). 2020 Mar 22;10(3): [PMID: 32235747]
  54. Cancers (Basel). 2021 Aug 13;13(16): [PMID: 34439241]
  55. Molecules. 2020 Jan 15;25(2): [PMID: 31952272]
  56. J Cell Sci. 2020 Mar 6;133(5): [PMID: 32144194]
  57. Molecules. 2019 Mar 21;24(6): [PMID: 30901941]
  58. Mol Biol Rep. 2021 May;48(5):4171-4180 [PMID: 34052966]
  59. Dis Markers. 2023 Jan 19;2023:9292536 [PMID: 36712920]
  60. Biochim Biophys Acta Rev Cancer. 2021 Apr;1875(2):188521 [PMID: 33556453]
  61. Cells. 2021 Jul 24;10(8): [PMID: 34440648]
  62. Crit Rev Eukaryot Gene Expr. 2021;31(4):71-79 [PMID: 34587437]
  63. Biomolecules. 2022 Jan 04;12(1): [PMID: 35053220]
  64. Cancers (Basel). 2020 Aug 24;12(9): [PMID: 32846967]
  65. Microorganisms. 2021 Oct 23;9(11): [PMID: 34835333]
  66. Oncologist. 2021 Feb;26(2):99-e217 [PMID: 33141975]
  67. Semin Immunol. 2014 Feb;26(1):54-74 [PMID: 24552665]
  68. Proc Natl Acad Sci U S A. 2019 Dec 10;116(50):25222-25228 [PMID: 31754025]
  69. Semin Cancer Biol. 2022 Nov;86(Pt 2):376-385 [PMID: 35568295]
  70. Life Sci. 2020 Oct 15;259:118297 [PMID: 32822718]

Word Cloud

Created with Highcharts 10.0.0ARDLGAP5TNBCcellinfiltrationgrowthp53signalingexpressionpathwayCD8TbreastcancerregulationstudyhighproliferationinhibitedinhibitsTriple-negativechallengingsubtypeunclearbiologicalmechanismsRecentlytranscriptionfactorandrogenreceptorgenegainedattentionpathogenesisfoundpositivecorrelationFurthermoreconfirmedcriticaldownstreamregulatortissuesKnockdownsignificantlymigrationinvasionobserveddirectlybindpromoterenhancingtranscriptionalactivitysuppressingactivationvivoexperimentsvalidateddownregulationtumorenhancedhighlightscrucialrolesimmuneTakentogetherpromotingtherebyimpactingTranscriptionalsuppressestriple-negativeCD8+TTumor

Similar Articles

Cited By